GlassScriptPhysician profile
Stephanie M Weaver
NPI 1538513080
$4,912.29
in general payments reported to CMS, 2019-2025
28 companies · $680 in 2025
The $680 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $585 · 2022: $1,110 · 2023: $1,414 · 2024: $1,124 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,035 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,034.77 |
| Education | $182.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $540.55 | 2022-2025 | |
| Leo Pharma INC. | $496.91 | 2021-2024 | Adbry |
| Pfizer INC. | $455.64 | 2021-2025 | |
| Janssen Biotech, INC. | $432.02 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $429.78 | 2022-2025 | |
| Abbvie INC. | $414.95 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $268.10 | 2022-2025 | Dupixent |
| Medimetriks Pharmaceuticals, INC. | $266.46 | 2022-2024 | Neo-Synalar, Clindacin Etz |
| E.R. Squibb & Sons, L.L.C. | $253.76 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $227.38 | 2022-2025 | Ilumya |
| Amgen INC. | $167.62 | 2021-2025 | Otezla, Enbrel |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $154.81 | 2021-2024 | Jublia |
| Lilly USA, LLC | $124.65 | 2021-2024 | Olumiant, Taltz |
| Galderma Laboratories, L.P. | $115.17 | 2022-2024 | |
| Journey Medical Corporation | $92.75 | 2021-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $75.03 | 2022-2023 | |
| Helsinn Therapeutics (U.S.), INC. | $61.05 | 2021-2023 | Valchlor |
| Epi Health, LLC | $51.68 | 2022 | |
| Incyte Corporation | $51.48 | 2022-2025 | Opzelura |
| Almirall LLC | $44.64 | 2021-2025 | Seysara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.19 | 2023-2024 | Spevigo |
| Ucb, INC. | $30.21 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $22.34 | 2022 | |
| Cipher Pharmaceuticals US LLC | $21.91 | 2025 | Natroba, Spinosad |
| Arcutis Biotherapeutics, INC. | $21.06 | 2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $16.78 | 2021 | |
| Dermavant Sciences, INC. | $16.30 | 2024 | Vtama |
| Botanix Sb INC | $16.07 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.